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Abstract
Background—HPTN 067/ADAPT evaluated tenofovir disoproxil fumarate/emtricitabine (TDF/
FTC) pre-exposure prophylaxis (PrEP) in women (South Africa) and men who have sex with men 
(Thailand, US). Participants received once-weekly directly observed TDF/FTC (DOT), and were 
then randomized to daily, time-driven, or event-driven PrEP. This report describes characterization 
of 12 HIV seroconversion events in this trial.
Methods—HIV rapid testing was performed at study sites. Retrospective testing included: 4th 
generation assays; HIV RNA testing; Western blot; an HIV-1/2 discriminatory assay; resistance 
testing; and antiretroviral (ARV) drug testing.
Results—Six of the 12 seroconverters received TDF/FTC in the DOT phase, but were not 
randomized (3 were acutely infected at enrollment; 2 were infected during the DOT phase; one 
was not randomized due to pregnancy). One of the six randomized participants had acute infection 
at randomization but was not diagnosed for 3–4 months because HIV rapid tests were non-
reactive; continued daily PrEP use was associated with false-negative antibody tests and low HIV 
RNA levels. The five participants infected after randomization included four with low adherence 
to the PrEP regimen, and one who reported a 7-day period without dosing prior to infection. Three 
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participants had TDF/FTC resistance (M184I, K65R), including two who received only four once-
weekly TDF/FTC doses; most TDF/FTC mutations were detected by next generation sequencing 
only.
Conclusions—In HPTN 067/ADAPT, participants who acquired HIV infection had infrequent 
PrEP dosing or low/suboptimal adherence. Sensitive assays improved detection of HIV infection 
and drug resistance. Drug resistance was observed with limited PrEP exposure.
Keywords
Pre-exposure prophylaxis; HIV seroconverter; antiretroviral drugs; resistance; tenofovir; 
emtricitabine
INTRODUCTION
A combined formulation of oral tenofovir disoproxil fumarate (TDF) and emtricitabine 
(FTC) is a component of first-line regimens for antiretroviral therapy (ART) in HIV-infected 
individuals.1 TDF/FTC can also be used for pre-exposure prophylaxis (PrEP).2–4 Daily oral 
TDF/FTC was approved by the United States (US) Food and Drug Administration (FDA) for 
PrEP in individuals at high risk of HIV acquisition in 2012,5 and is now recommended by 
the US Centers for Disease Control (CDC) and World Health Organization (WHO) for 
prevention of HIV infection in diverse risk groups.6,7 The IPERGAY8 study demonstrated 
that an event-driven non-daily TDF/FTC regimen can also reduce the risk of HIV infection 
in men who have sex with men (MSM).
A meta-analysis of randomized controlled trials and observational studies showed that high 
adherence was significantly associated with a protective effect of TDF and TDF/FTC PrEP.4 
In the iPrEx study, participants in the TDF/FTC arm who had detectable levels of study 
drugs had a >92% risk reduction (95% CI: 40–99%) compared to those without detectable 
drug.9 In other trials, such as Fem-PrEP10 and VOICE,11 low PrEP efficacy was attributed to 
low adherence to the study regimens.
HIV drug resistance can arise in individuals who become infected while using PrEP. 
However, most studies show that resistance to tenofovir (TFV) and FTC arises infrequently 
in the setting of TDF/FTC PrEP use.4,12 In a report that included results from eight 
randomized clinical trials, resistance emerged in 5.9% of 305 seroconverters.3 Higher rates 
of TDF/FTC resistance were observed in those who had undiagnosed acute HIV infection at 
the time of PrEP initiation.4,12 M184I/V drug resistance mutations, which confer resistance 
to FTC, are seen more commonly in the setting of PrEP than the K65R mutation, which 
confers resistance to TDF.12 Emergence of resistance in individuals who become infected 
while using PrEP may limit options for subsequent ART.
Detailed characterization of seroconversion events in PrEP trials can help distinguish 
between infections due to infrequent dosing/non-adherence and true breakthrough 
infections, and can provide information on the relationship between PrEP exposure and 
emergence of drug resistance. In this study, we characterized incident HIV infections in the 
HIV Prevention Trials Network (HPTN) 067/ADAPT trial.13–15 The trial included a once-
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weekly directly observed treatment (DOT) phase followed by a period of self-administered 
treatment (SAT) that included three study arms with different TDF/FTC PrEP regimens 
(daily, time-driven, and event-driven). The trial was designed to compare the coverage of 
sexual events, number of doses needed for coverage, and self-reported side-effects/
symptoms associated with daily vs. non-daily PrEP use. The DOT phase of the HPTN 067/
ADAPT trial was implemented prior to randomization to establish individual 
pharmacokinetic (PK) parameters to help interpret PK-based adherence assessments 
performed during the SAT phase of the study. Unfortunately, a priori estimates of the half-
life of tenofovir diphosphate (TFV-DP) in peripheral blood mononuclear cells (PBMCs) 
were too long, and weekly DOT dosing was too infrequent to achieve consistently 
measurable drug concentrations one week after dosing. While inclusion of the DOT phase 
did not provide the desired information (PK parameters in individual study participants), it 
did provide an opportunity to evaluate infections that occurred in the setting of infrequent 
(once-weekly) observed drug dosing. Infections that occurred during the SAT phase of the 
trial were also analyzed. Data analyzed in this report includes self-reported PrEP use and 
results obtained with a panel of HIV diagnostic tests, HIV viral load testing, antiretroviral 
(ARV) drug testing, and HIV drug resistance testing.
METHODS
Study cohort
Samples and data were obtained from the HPTN 067/ADAPT study, a Phase 2 randomized, 
open-label trial of the use of oral TDF/FTC (300 mg TDF/200 mg FTC tablet) PrEP among 
HIV-uninfected individuals (NCT: 01327651, 2011–2014). The study enrolled 622 
participants in Cape Town, South Africa (women who have sex with men, N=191), 
Bangkok, Thailand (MSM and transgender women, N=193), and New York, USA (MSM 
and transgender women, N=238). The study included a 6-week lead-in period with five 
once-weekly directly observed TDF/FTC doses (DOT phase; doses were administered at 
enrollment and weeks 1–4 with no dosing at week 5). At the 6-week visit, participants were 
randomized to one of three PrEP regimens: daily (once daily dosing); time-driven (twice 
weekly dosing with an additional dose following sexual intercourse); and event-driven (24–
48 hours before and within 2 hours after sexual intercourse). Study drug was dispensed and 
participants were tested for HIV infection at monthly study visits during the SAT phase 
(weeks 6–30). The final study visit was at week 34. All participants were instructed not to 
take more than two pills per 24-hour period, or more than seven pills per week.
Self-reported dosing
After randomization, weekly interviews were conducted by phone or in person with an 
interviewer who was not involved in other study activities. Data from electronic dose 
monitoring (WisePill) was discussed to determine which device opening events were 
reflective of dosing and which were not; the date and time of sex events were also recorded.
HIV testing
HIV testing was performed at enrollment, at weeks 4 and 6, and at monthly follow-up visits. 
Two HIV rapid tests were performed in parallel at study sites; tests used included: the Uni-
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gold Recombigen HIV Test (Trinity Biotech PLC, Bray, County Wicklow, Ireland); the 
Determine HIV-1/2 Test (Abbott Laboratories, Abbott Park, IL); and the OraQuick Advance 
Rapid HIV-1/2 Antibody Test (Orasure Technologies Inc., Bethlehem, PA). PrEP was 
discontinued if one or both of the HIV rapid tests was reactive. In these cases, HIV infection 
was confirmed at study sites using a qualitative HIV RNA assay (APTIMA HIV-1 RNA 
Qualitative Assay, Hologic Gen-Probe INC., San Diego, CA). Additional HIV testing was 
performed retrospectively at the HPTN Laboratory Center (Johns Hopkins University, 
Baltimore, MD) using a panel of assays (Figure 1).
Drug resistance testing
Drug resistance testing was performed retrospectively at the HPTN Laboratory Center for 
plasma samples with viral loads >400 copies/mL. Two methods were used for drug 
resistance testing: the ViroSeq HIV-1 Genotyping System (Abbott Molecular, Des Plains, 
IL) and next generation sequencing (NGS). HIV subtyping was performed using HIV pol 
sequences obtained from the ViroSeq system, as described.16 NGS was performed using 
viral RNA that was extracted from plasma samples using the ViroSeq system; methods used 
for NGS are described in Supplemental Digital Content 1. HIV drug resistance reports were 
generated using the Stanford University HIV drug resistance database.17
ARV drug testing
ARV drug testing was performed retrospectively by the HPTN Laboratory Center by liquid 
chromatography tandem mass spectrometry (LC-MS/MS) using plasma samples (all three 
sites), PBMC samples (South Africa and Thailand), and dried blood spots (DBS) samples 
(US).18–20 The lower limit of quantification (LLOQ) for these assays are: plasma: tenofovir 
(TFV) and FTC 0.31 ng/mL,18 PBMC: TFV-DP 2.5 fmol/sample, emtricitabine triphosphate 
(FTC-TP) 0.1 pmol/sample, the average LLOQ based on cells assayed per sample is 0.57 
fmol/106 cells for TFV-DP and 0.014 pmol/106 for FTC-TP,20 DBS: TFV-DP 31.25 fmol/
punch, FTC-TP 0.125 pmol/punch.21 Plasma and PBMC drug concentrations were 
interpreted based on results from a dose ranging PK study with directly observed TDF/FTC 
dosing.20
Ethics statement
All study participants provided written informed consent for participation in the HPTN 067/
ADAPT study. The study was approved by the participating academic institutions and ethics 
committees for each study site.
RESULTS
Twelve study participants acquired HIV infection (8/191 in South Africa; 2/193 in Thailand; 
2/238 in the US, Table 1). HIV subtypes were consistent with subtypes prevalent at each 
study site (South Africa: subtype C; Thailand: CRF01_AE; US: subtype B). All 12 
participants received once-weekly observed TDF/FTC doses in the DOT phase. Six 
participants were not randomized due to HIV infection or pregnancy (Figure 1A) and six 
were randomized at the 6-week study visit (2 in each study arm; Figures 1B–D).
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Detection of HIV infection using third generation HIV rapid tests
Participants were tested with two 3rd generation HIV rapid tests at each study visit. 
Retrospective testing using 4th generation HIV tests, HIV RNA tests, and other assays 
revealed that the rapid tests often missed HIV infection. In 9/12 cases, both of the rapid tests 
were non-reactive at the first HIV positive visit. In these cases, HIV-infected participants 
continued to use PrEP until their infection was detected at the study site. A qualitative HIV 
RNA assay was positive in all 12 cases at the first HIV-positive visit; the HIV viral load was 
≤400 in four cases. In 8/12 cases, retrospective testing revealed that participants had acute 
HIV infection at the first HIV-positive visit; in five of these cases, positive tests results were 
obtained for HIV RNA assays only; in the other three cases, one or both of the 4th generation 
tests was also reactive. In two other cases where HIV infection was missed by one or both of 
the rapid tests, other HIV tests indicated the presence of anti-HIV antibodies. In one case, 
the Western blot was indeterminate and the discriminatory assay was negative (Case 4); in 
the other case, the Western blot was indeterminate and the discriminatory test was positive 
(Case 5). In 4/12 cases, one or both of the rapid tests was still non-reactive at the 
seroconversion visit (Cases 1, 2, 5, and 7); in one case (Case 7), both rapid tests were non-
reactive at multiple study visits.
Analysis of HIV infection in participants who were not randomized to a PrEP regimen
Six participants were not randomized (Figure 1A); these participants received only once-
weekly TDF/FTC dosing in the DOT phase of the trial. Three had acute HIV infection at 
enrollment that was not detected at the study sites (Cases 1–3), and two acquired HIV 
infection during the DOT phase (Cases 4 and 5). HIV infection was diagnosed at the study 
site at the 4-week visit in four cases; those participants did not receive TDF/FTC at week 4. 
In the fifth case (Case 4), HIV infection was diagnosed at the 5-week visit; that participant 
received all five DOT doses. One participant was not randomized to a PrEP regimen due to 
pregnancy (Case 6); this participant acquired HIV infection between the 22-week and 26-
week study visits.
ARV drug testing was performed using plasma samples collected at week 4 (prior to dosing) 
and week 5. TFV and/or FTC was detected in plasma at one or both visits in five of the six 
cases; FTC was detected at week 6 in one of two participants who received TDF/FTC at 
week 4 (Case 6). PBMC testing was performed for the five participants. TFV-DP and/or 
FTC-TP was detected at week 4, 5, or 6 in all five cases. Plasma testing was performed at 
weeks 22 and 26 for the participant who was not randomized due to pregnancy (Case 6); 
TFV and FTC were not detected at those visits.
Analysis of HIV infection in participants who were randomized to a PrEP regimen
The remaining six participants acquired HIV infection after randomization (Figure 1B–D). 
PrEP was discontinued when one or both of the HIV rapid tests was reactive. Two 
participants were randomized to the daily PrEP study arm (Figure 1B). In Case 7, a female 
participant had undiagnosed acute infection at the 6-week randomization visit; HIV testing 
was negative at week 5, indicating that this participant was infected 1–2 weeks after 
receiving 5 once-weekly DOT doses. This participant continued to use PrEP for 3–4 months 
after infection (from week 6 to week 22), until the infection was detected by HIV rapid 
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testing at the study site; the participant reported taking 84.4% of the assigned doses during 
this period. Study drugs were detected in plasma and PBMCs at all visits tested during the 
SAT phase (weeks 10–22), but the concentration of drugs detected at some visits were 
consistent with less than daily PrEP use (TFV concentration corresponded to 7 doses/week 
at week 10, ≥4 doses/week at week 14, 7 doses/week at week 18, and 7 doses/week at week 
22). At the visit before the participant was diagnosed with HIV infection at the study site 
(week 18), the concentration of TFV-DP in PBMC was consistent with 1 dose/week (based 
on comparison to her data from the DOT phase); the discrepancy between plasma and 
PBMC drug concentrations at week 18 suggests that this participant may have taken the drug 
shortly before the study visit (“white coat effect”). HIV viral loads were persistently low in 
this case (<400 copies/mL at all but one visit; 650 copies/mL at week 18). Fourth generation 
HIV assays were reactive after infection, but had low signal-to-cutoff ratios (<2.5 for the 
ARCHITECT assay; <9 for the Bio-Rad assay). The APTIMA qualitative HIV RNA assay 
was initially positive, but was negative at subsequent visits; this assay has a limit of 
detection of 40 copies/mL HIV RNA. Resistance testing results were not obtained in this 
case because the viral load was low at all visits following HIV infection. In Case 8, the 
participant acquired HIV infection between weeks 10 and 14 (4–8 weeks after 
randomization). Study drugs were detected in only one plasma sample and one DBS sample 
collected during the SAT phase. These results suggest that the participant was not adherent 
to the daily PrEP regimen.
Two participants were randomized to the time-driven study arm (Figure 1C). In Case 9, the 
participant was infected between weeks 18 and 22 (12–16 weeks after randomization). Study 
drugs were detected in only two of four plasma samples collected during the SAT phase 
(weeks 10–22); low levels of study drugs were detected in PBMC samples at two of these 
visits. These results suggest that the participant was not adherent to the time-driven study 
regimen. In Case 10, HIV infection was diagnosed at the study site at week 18. 
Retrospective testing revealed that the participant had acute HIV infection at the prior visit 
(week 14, 8 weeks after randomization); PrEP was continued in the 4-week interval between 
these two visits. Study drugs were detected in plasma and PBMCs at all visits during the 
SAT phase (weeks 10–18); the drug concentrations were higher than expected for the time-
driven regimen (TFV concentration corresponded to 7 doses/week at week 10, multiple 
doses/day at week 14, and 7 doses/week at week 18). The concentration of TFV-DP in 
PBMC at week 18 was also higher than expected (consistent with 7 doses/week). Self-
reported data indicated that this participant took a dose every 3–4 days for the first 6 weeks 
after randomization. She continued to take 2 pills/week over the next two weeks, but took 
those doses at irregular intervals. She reported taking a pill 4 days prior to the acute 
infection visit, after taking no pills for 7 days.
Two participants were randomized to the event-driven study arm (Figure 1D). In Case 11, 
HIV infection was diagnosed at the study site at week 34, 4 weeks after the end of the SAT 
phase. Retrospective testing revealed that the participant had acute HIV infection at the prior 
visit (week 30, 24 weeks after randomization). Study drugs were detected in only one of 
seven plasma samples and two of three PBMC samples collected during the SAT phase (at 
weeks 10–30). In Case 12, HIV infection was diagnosed at the study site week 22. 
Retrospective testing revealed that the participant had acute HIV infection at the prior visit 
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(week 18, 12 weeks after randomization); PrEP was continued in the 4-week interval 
between these two visits. Study drugs were detected in only two of four plasma samples and 
one of two PBMC samples collected during the SAT phase (at weeks 10–22), indicating 
infrequent PrEP use. Both participants reported infrequent sex events with low adherence to 
the event-driven regimen (42% of assigned doses taken in Case 11; 67% of assigned doses 
taken in Case 12).
HIV drug resistance
Samples from the 12 seroconverters were tested for HIV drug resistance. Mutations 
associated with resistance to the study drugs were detected in three cases using NGS. This 
included two cases where participants had acute HIV infection at enrollment (Case 1: K65R 
was detected in 24.7% of sequences; Case 2: M184I was detected in 3.5% of sequences), 
and one case where the participant was randomized to the time-driven arm (Case 10: K65R 
was detected in 3.9% of sequences; M184I was detected in 62.3% of sequences). In the first 
two cases (Cases 1 and 2), participants received only four once-weekly DOT doses of PrEP 
(at study enrollment and at weeks 1–3) before resistance was detected. Using a genotyping 
assay based on population sequencing (ViroSeq), resistance to study drugs was detected in 
only one of the three cases (Case 10); in that case, only one of the two drug resistance 
mutations was detected (M184I). Resistance to other ARV drugs was detected in two cases 
(resistance to non-nucleoside reverse transcriptase inhibitors (NNRTIs, Cases 2 and 8).
DISCUSSION
This report presents analysis of 12 cases of HIV infection in the HPTN 067/ADAPT trial. 
This included three cases where participants were acutely infected at enrollment, two cases 
where participants were infected during the once-weekly DOT phase, and six cases where 
participants were infected after randomization to one of three self-administered PrEP 
regimens. In the last case, a participant was not randomized due to pregnancy and was 
infected during the follow-up period. In the seven of eight cases that occurred in the context 
of PrEP use, participants had infrequent PrEP dosing (e.g., once-weekly DOT only) or low/
suboptimal adherence. In one case, adherence was high during most of the follow-up period; 
infection followed a 7-day period with no dosing (one missed dose in the time-driven arm).
The findings in this report highlight the higher diagnostic yield of sensitive assays for HIV 
diagnosis in the setting of PrEP use. In 9/12 cases, HIV infection was missed by two 3rd 
generation HIV rapid tests at the first HIV-positive visit; in eight of these cases, rapid tests 
were non-reactive at the first HIV-positive visit because the participant had acute HIV 
infection. Frequent detection of acute HIV infection in this cohort likely reflected the short 
intervals between study visits. In seven cases, one or both of the 4th generation assays was 
also non-reactive at the first HIV-positive visit. In three cases, one or both of the rapid tests 
also missed infection at subsequent study visits where both 4th generation tests were 
reactive. Failure to detect HIV infection using 3rd generation rapid tests resulted in 
continued PrEP use in eight cases. In one case, PrEP use was continued for 3–4 months after 
infection. In three of these cases, participants developed resistance to the study drugs (see 
below). In the iPrEx study, most HIV-infected individuals who had non-reactive HIV rapid 
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tests had a positive HIV RNA test.22 In HPTN 067/ADAPT, four of eight participants who 
had acute infection at the first HIV-positive visit had a very low viral load (≤400 copies/mL); 
in these cases, infection was only detected using a sensitive, FDA-cleared qualitative HIV 
RNA assay. In the case where PrEP use was continued for 3–4 months after HIV infection, 
HIV RNA levels dropped below the level of detection for this sensitive assay, and the signal-
to-cutoff ratios for both 4th generation tests remained low. This case illustrates that 
prolonged daily PrEP use in some individuals with undiagnosed HIV infection may be 
associated with low-level antibody production and sustained viral suppression.
In a study in rhesus macaques, PrEP was associated with delayed antibody maturation and 
low viral load.23 In the Partners PrEP study, TDF or TDF/FTC PrEP was associated with 
delayed anti-HIV antibody formation (delayed time to develop a positive Western blot).24 In 
the CAPRISA study, antibody maturation was delayed in women receiving vaginal TFV gel 
for PrEP.25 In that study, antibody maturation was evaluated using assays developed for 
cross-sectional HIV incidence estimation.25 In contrast, detection of HIV seroconversion 
was not delayed in two other PrEP trials.9,26 These findings suggest that it may be difficult 
to diagnose HIV infection in some individuals who are taking TDF-based PrEP, particularly 
if less sensitive assays are used for HIV screening, and that PrEP use in cohorts and 
populations could also impact estimation of HIV incidence using cross-sectional surveys.27
In HPTN 067/ADAPT, resistance to study drugs was detected in three of 12 seroconverters. 
In two cases, resistance mutations were detected by NGS only; in the third case, one 
mutation was detected by routine HIV genotyping (M184I) and one was detected by NGS 
only (K65R). This demonstrates the additional diagnostic yield in this setting when more 
sensitive methods are used for analysis of HIV drug resistance. In two of these cases, 
participants with undiagnosed acute HIV infection were only exposed to four once-weekly 
doses of TDF/FTC; this indicates that very limited exposure to PrEP is sufficient to induce 
resistance in individuals with early/acute HIV infection.
Detailed characterization of seroconversion events in this study revealed that all 12 incident 
infections occurred in the setting of infrequent PrEP dosing or low/suboptimal adherence, 
and that drug resistance can arise with minimal exposure to PrEP. This report also highlights 
the importance of using sensitive assays for HIV diagnosis and resistance testing in the 
setting of PrEP. Identification of HIV infections before starting PrEP and prompt 
discontinuation of PrEP in those who become infected after starting PrEP should reduce the 
risk of HIV drug resistance.
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Figure 1. Laboratory test results for HIV-infected participants
Laboratory test results are shown for 6 participants who were not randomized (Figure 1A, 
Cases 1–6) and 6 participants who were randomized to the daily, time-driven, or event-
driven study arms (Figure 1B–D, Cases 7–12). The shaded area indicates the period when 
participants received once-weekly directly observed therapy (DOT); four participants did not 
receive DOT at the week 4 visit because one or both of the HIV rapid tests was positive 
(Cases 1, 2, 3, and 5). One participant was not randomized due to pregnancy (Case 6); this 
participant was followed during the study, but did not receive PrEP in the SAT (self-
administered therapy) phase. The remaining six participants were randomized to one of three 
PrEP regimens at week 6 (SAT). PrEP was discontinued when one or both of the HIV rapid 
tests was reactive; in one case, the participant stopped PrEP at the end of the SAT phase 
(week 30) and had reactive rapid tests at the next visit in the follow-up phase (at week 34, 
Case 11). Reactive/positive test results are shown in bold font. Two HIV rapid tests were 
performed in parallel at study sites (Site rapid); results are shown as reactive (R) or non-
reactive (NR). HIV infection was confirmed at study sites using the APTIMA HIV-1 RNA 
Qualitative Assay (Site RNA Qual; limit of detection: <40 copies/mL, Hologic, 
Marlborough, Massachusetts). Additional testing was performed retrospectively at the 
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HPTN Laboratory Center (LC). This included two 4th generation tests (LC Arc: 
ARCHITECT HIV Ag/Ab Combo Assay, Abbott Diagnostics, Weisbaden, Germany; LC 
BR: GS HIV Combo Ag/Ab Enzyme Immunoassay, Bio-Rad Laboratories, Redmond, WA). 
The signal to cut-off ratios (S/C) for the 4th generation tests are shown in parenthesis; a ratio 
<1 is considered to be nonreactive. HIV infection was confirmed using a Western blot assay 
(LC WB, Genetics System HIV-1 Western blot test, Bio-Rad Laboratories) and a 
discriminatory assay (LC Disc, the Multispot HIV-1/HIV-1 Rapid test or Geenius HIV 1/2 
Supplemental Assay, Bio-Rad Laboratories]); an asterisk indicates that the Geenius assay 
was used; other samples were tested using the Multispot assay. Western blot results were 
reported as positive (P), indeterminate (IND), or negative (N). Viral load testing (LC VL) 
was performed using a modified version of the COBAS AMPLICOR HIV-1 MONITOR test 
(Roche Diagnostics, Branchburg, NJ) with a lower limit of detection of 400 HIV RNA 
copies/mL. HIV drug resistance testing was performed using the ViroSeq HIV-1 Genotyping 
System (Resist VS) and a next generation sequencing assay with a mutation cut-off of 2% 
(Resist NGS). Mutations associated with resistance to tenofovir (TFV) and emtricitabine 
(FTC) are shown in bold font; other major drug resistance mutations are shown in regular 
font. TFV and FTC testing was performed using plasma samples (Plasma TFV/FTC, 
reported as ng/mL). TFV-diphosphate (TFV-DP) and FTC-triphosphate (FTV-TP) testing 
was performed using peripheral blood mononuclear cell PBMC samples (PBMC TFV-DP, 
reported as fmol/106 cells; PBMC FTC-TP, reported as pmol/106 cells), with one exception: 
testing for TFV-DP and FTC-TP was performed using DBS samples in Case 8 (reported as 
fmol/punch). Antiretroviral (ARV) test results below the limit of detection for each assay are 
shown with a dash (−). The s/c values for the 4th generation tests and the study drug 
concentrations values less than 10 are rounded to one decimal place; the values greater than 
10 are rounded to the integer.
Abbreviations: SA; South Africa; US: United States; TH: Thailand; En: enrollment; w: 
week; NR: nonreactive; R: reactive; P: positive; N: negative; IND, indeterminate; RNA 
Qual: qualitative HIV RNA testing; S/C: signal to cut-off ratio; LC, HPTN Laboratory 
Center; Arc: ARCHITECT HIV Ag/Ab Combo Assay; BR: GS HIV Combo Ag/Ab Enzyme 
Immunoassay; Disc: Multispot HIV-1/HIV-1 Rapid test or Geenius HIV 1/2 Supplemental 
Discriminatory Assay; WB: Western Blot; VL: viral load; Resist: Resistance; VS: the 
ViroSeq HIV-1 Genotyping System; NGS: next generation sequencing; DBS: dried blood 
spot; TFV: tenofovir; FTC: emtricitabine; TFV-DP: tenofovir-diphosphate; FTC-TP: 
emtricitabine-triphosphate; DOT: directly observed therapy; SAT, self-administered therapy; 
F/U: follow-up; ND: not determined.
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